The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL

B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as the BCL-2 inhibitor ABT-199, is the development of acqu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Di Grande, Alessandra, Peirs, Sofie, Donovan, Paul D., Van Trimpont, Maaike, Morscio, Julie, Lintermans, Beatrice, Reunes, Lindy, Vandamme, Niels, Goossens, Steven, Nguyen, Hien Anh, Lavie, Arnon, Lock, Richard B., Prehn, Jochen H. M., Van Vlierberghe, Pieter, Ní Chonghaile, Triona
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045507/
https://ncbi.nlm.nih.gov/pubmed/33830207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004177
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados